A negative drug screen means fewer things in 2026 than it did two years ago. Not because the tests got worse, but because the supply they were designed around has moved. Two substances now showing up routinely in the illicit opioid supply do not appear on a standard point-of-care panel at all, and a clinic reading a clean cup has no way to know that from the cup.
What changed in the supply this year
Medetomidine. On 2 April 2026 the CDC issued a health advisory on medetomidine, a veterinary sedative appearing in the illegal fentanyl supply. Testing between July and December 2025 found it in roughly 35% of opioid-positive samples at 10 of 20 sentinel sites, and 98% of medetomidine-positive samples also contained fentanyl. It is not a substitute for fentanyl; it travels with it.
Last week North Carolina Health News reported that medetomidine has overtaken xylazine as the dominant adulterant in that state's supply. Clinicians there describe a withdrawal syndrome that is harder to manage than xylazine, with cases requiring intensive care and days of sedation.
Carfentanil. Labcorp's June 2026 drug trends report found carfentanil in more than 10% of fentanyl-positive samples, after it was essentially absent in 2021 and 2022. The same report shows xylazine declining from its historical peak, which is the other half of the same story: the sedative layer of the supply is being replaced rather than removed.
Why the panel does not see it
The CDC advisory states it plainly: medetomidine "is not typically included in hospital rapid drug screens." There is no line on a standard cup for it.
Carfentanil is a harder case, because it looks like it should be covered. It is a fentanyl analog, and a panel with a fentanyl line might reasonably be expected to flag it. A study in the Journal of Analytical Toxicology tested 19 commercial immunoassay kits against 30 fentanyl analogs and found that carfentanil "was only detected by kits specifically designed for its recognition." Structurally distant analogs were poorly detected across the board. An immunoassay recognises a shape, and analogs that drift far enough from that shape stop registering.
Worth separating two different questions here. Whether a substance is on the panel is a purchasing decision. Whether the assay reliably detects what it claims to cover is a chemistry problem, and no amount of adding panels solves it.
What the regulation actually requires
The testing obligation itself has not changed. Under 42 CFR 8.12, opioid treatment programs must use drug tests "that have received the Food and Drug Administration's marketing authorization," at a frequency matched to the patient's response and stability in treatment, "but no fewer than eight random drug tests per year patient."
Two things follow from that sentence that are easy to miss.
First, FDA marketing authorization is a requirement, not a preference. A great deal of point-of-care screening product on the market is labelled For Forensic Use Only. That designation is not a formality or a disclaimer about liability. It means the device has not been cleared for clinical diagnostic use, and a device carrying it does not satisfy the standard above for required random testing. Forensic-use products have real applications in research and investigative screening. Required patient testing in a certified program is not one of them. It is worth reading the regulatory status line on every cup and card in your supply room, including ones that have been on the shelf for years.
Second, the same regulation is explicit that the testing requirement "does not preclude distribution of legal harm reduction supplies that allow an individual to test their personal drug supply for adulteration with substances that increase the risk of overdose." Supply-checking strips and patient screening are two different activities, governed differently, and the rule permits both. What did change is who pays: SAMHSA withdrew federal grant funding for test strips this spring, which moved that line from a grant budget to an operating budget for a lot of programs.
The part nobody tells you when you go looking for a fentanyl panel
The obvious response to everything above is to buy a cup with a fentanyl line on it. We went looking for one that meets the standard, and the result is worth reporting.
Every FDA-cleared multi-drug urine cup we could identify, working back through 2019, stops short of fentanyl. There is no FDA device classification for fentanyl drug-screening test systems at all. Cups that do carry a fentanyl line are, in our experience of the market, labelled For Forensic Use Only.
Fentanyl testing that does hold FDA clearance exists, but not in the format most clinics are shopping for:
Analyzer-based assays. JANT Pharmacal's fentanyl assay was the first FDA-cleared fentanyl immunoassay, at a 1 ng/mL cut-off, running on Beckman AU series analyzers. It is CLIA moderate complexity, not waived, which is a different certificate and different personnel requirements. Carolina Liquid Chemistries' Fentanyl Urine Detect, distributed by Medline, is FDA-cleared at 1.0 ng/mL and runs on the RYAN fluorescence analyzer.
A rapid visual test, as of this year. In April 2026 Labcorp launched what it describes as the first FDA-cleared rapid fentanyl test of its kind manufactured in the United States. It detects norfentanyl, returns a result in about ten minutes, and is cleared for use by qualified professionals in CLIA-certified settings.
So the honest position for a program that needs fentanyl on its required panel today is that a waived point-of-care cup is not the answer, because that product does not currently exist. The answer is a send-out to a laboratory, or an analyzer, or a cleared rapid test run in a CLIA-certified setting. Any supplier telling you otherwise is either selling you a forensic-use product for a clinical purpose or has not read the label.
What this means in practice
None of the above argues for testing less, or for treating a screen as unreliable. It argues for knowing precisely what your screen covers.
A point-of-care cup answers one question well: is a substance on this panel present above this cut-off. It does not answer whether the patient encountered something the panel was never built to see. When the clinical picture and the screen disagree, the screen is the weaker evidence, and confirmatory laboratory testing is what resolves it.
Three practical checks worth running against your own supply room:
Know the regulatory status of every device you use for required testing. FDA-cleared and CLIA-waived, or For Forensic Use Only. If the box does not say, the data sheet does.
Know your panel line by line. Not the panel count. A twelve-panel and a thirteen-panel can differ by a substance that matters to your population, and the count alone will not tell you which.
Know your escalation path. Prolonged sedation that does not respond to naloxone, or a withdrawal presentation that does not fit the history, are the situations the CDC advisory was written for. A negative cup does not close that question.
Our drug screening range, with the panel contents, cut-off levels and regulatory status listed on every product, is at medsupplylab.com/drug-test. If you are unsure which configuration matches what your program is required to run, ask us before you order rather than after.
— Med Supply Lab
